Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-11-06, Stock:LLY, The news for the past five days is as follows:
2018-10-30: NEWS1: Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View.NEWS2: Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View.NEWS3: Pfizer Missed Analysts’ Third-Quarter Revenue Estimates.NEWS4: Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View.NEWS5: Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance.NEWS6: Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance.NEWS7: Sanofi: Analysts’ Recommendations on October 30.NEWS8: Sanofi’s Q3 Estimates: Expect Revenue Growth.NEWS9: Your first trade for Tuesday, Oct 30.NEWS10: Your first trade for Tuesday, Oct 30.NEWS11: This is Why Eli Lilly (LLY) is a Great Dividend Stock.NEWS12: Better Buy: Celgene Corporation vs. Gilead Sciences.NEWS13: Better Buy: Celgene Corporation vs. Gilead Sciences.NEWS14: Elanco Animal Health Names Todd Young CFO - Quick Facts.NEWS15: Elanco Animal Health Names Todd Young CFO - Quick Facts.
2018-10-31: NEWS1: Eli Lilly (LLY) Gains But Lags Market: What You Should Know.NEWS2: The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead.NEWS3: The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead.NEWS4: The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead.NEWS5: Sanofi's (SNY) Q3 Earnings and Sales Surpass Estimates.NEWS6: Sanofi's (SNY) Q3 Earnings and Sales Surpass Estimates.NEWS7: XLV, MDT, ABT, LLY: ETF Inflow Alert.NEWS8: XLV, MDT, ABT, LLY: ETF Inflow Alert.NEWS9: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS10: Dr. Reddy's Launches Atomoxetine Capsules, Generic Version Of Strattera, In U.S..NEWS11: Dr. Reddy's Launches Atomoxetine Capsules, Generic Version Of Strattera, In U.S..
2018-11-01: NEWS1: Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View.NEWS2: Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View.NEWS3: Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales.NEWS4: Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales.NEWS5: Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates &apos;18 View.NEWS6: Novo Nordisk (NVO) Q3 2018 Earnings Conference Call Transcript.NEWS7: United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips.NEWS8: Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View.NEWS9: Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View.NEWS10: Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?.NEWS11: Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?.NEWS12: Eli Lilly (LLY) to Report Q3 Earnings: What&apos;s in the Cards?.NEWS13: Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises &apos;18 View.NEWS14: 3 Pharma Stocks to Make a Portfolio Feel Better.NEWS15: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS16: Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure.NEWS17: Upbeat sales lift Novo Nordisk as drugmaker weathers U.S. pricing pressure.NEWS18: Eli Lilly (LLY) Gains But Lags Market: What You Should Know.NEWS19: Eli Lilly (LLY) Gains But Lags Market: What You Should Know.
2018-11-02: NEWS1: AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues.NEWS2: AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues.NEWS3: AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues.NEWS4: Earnings Estimates Coming Down.NEWS5: Earnings Estimates Coming Down.NEWS6: Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss.NEWS7: Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss.NEWS8: Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise.NEWS9: Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise.NEWS10: A Look at Merck’s Diabetes and Women’s Health Business.NEWS11: Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus.NEWS12: Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus.NEWS13: Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus.
2018-11-05: NEWS1: Berkshire Hathaway and Lilly climb; Sysco and MGM sink.NEWS2: Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3.NEWS3: Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3.NEWS4: Health Care Sector Update for 11/05/2018: LLY,BHC,BTAI,FOLD.NEWS5: Health Care Sector Update for 11/05/2018: LLY,BHC,BTAI,FOLD.NEWS6: Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines.NEWS7: Pre-Market Earnings Report for November 6, 2018 :  LLY, CVS, BDX, EMR, REGN, APD, TRI, ADM, ABC, TDG, BR, HSIC.NEWS8: Pre-Market Earnings Report for November 6, 2018 :  LLY, CVS, BDX, EMR, REGN, APD, TRI, ADM, ABC, TDG, BR, HSIC.NEWS9: Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?.NEWS10: Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?.NEWS11: Health care companies and banks climb; Apple falls.NEWS12: Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3.NEWS13: Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?.NEWS14: US stocks rise as Berkshire climbs; Apple sinks again.NEWS15: How Wall Street Analysts View Teva Pharmaceutical.NEWS16: US stocks are higher as Berkshire climbs; Apple sinks again.NEWS17: Eli Lilly Gets Ready For First Report Post-Elanco IPO.NEWS18: Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes.NEWS19: Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?.NEWS20: Disney, Michael Kors, Ralph Lauren and Eli Lilly are part of Zacks Earnings Preview.NEWS21: Disney, Michael Kors, Ralph Lauren and Eli Lilly are part of Zacks Earnings Preview.NEWS22: Disney, Michael Kors, Ralph Lauren and Eli Lilly are part of Zacks Earnings Preview.NEWS23: Top 5 Things to Know in The Market on Monday.NEWS24: Lilly says diabetes drug Trulicity reduces heart risks in trial.NEWS25: Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes.NEWS26: Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease.NEWS27: Eli Lilly: REWIND Trial Demonstrates MACE Reduction By Trulicity - Quick Facts.NEWS28: Eli Lilly: REWIND Trial Demonstrates MACE Reduction By Trulicity - Quick Facts.

Answer: Decrease